Diabetic dyslipidemia or ‘diabetes lipidus’?
暂无分享,去创建一个
[1] Ž. Reiner. Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & clinical pharmacology.
[2] J. Born,et al. Enhancing influence of intranasal interleukin‐6 on slowwave activity and memory consolidation during sleep , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] Ž. Reiner. How to improve cardiovascular diseases prevention in Europe? , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[4] Nikolaus Marx,et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.
[5] M. Cooper,et al. UKPDS and the legacy effect. , 2008, The New England journal of medicine.
[6] A. Jenkins,et al. Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications , 2008, Diabetes Care.
[7] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[8] Jian-Dong Li,et al. Extracellular Signal-Regulated Kinase 5 SUMOylation Antagonizes Shear Stress–Induced Antiinflammatory Response and Endothelial Nitric Oxide Synthase Expression in Endothelial Cells , 2008, Circulation research.
[9] Ž. Reiner,et al. The burden of hyperlipidaemia and diabetes in cardiovascular diseases , 2007, Fundamental & clinical pharmacology.
[10] Ž. Reiner,et al. Clinical Study on the Effect of Simvastatin on Paraoxonase Activity , 2007, Arzneimittelforschung.
[11] M. Chapman. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences , 2007, Diabetes & vascular disease research.
[12] P. Durrington,et al. Lipids and their metabolism , 2007 .
[13] T. M. Lewin,et al. Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[14] D. Mikhailidis,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.
[15] K. Channon,et al. Endothelial Nox2 Overexpression Potentiates Vascular Oxidative Stress and Hemodynamic Response to Angiotensin II: Studies in Endothelial-Targeted Nox2 Transgenic Mice , 2006, Circulation research.
[16] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[17] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.
[18] D. Harrison,et al. Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease , 2006, European Journal of Clinical Pharmacology.
[19] W. Benzer,et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? , 2005, Diabetes care.
[20] H. Ginsberg,et al. Regulation of plasma triglycerides in insulin resistance and diabetes. , 2005, Archives of medical research.
[21] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[22] R. Krauss. Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.
[23] B. Berk,et al. Big Mitogen-Activated Protein Kinase (BMK1)/ERK5 Protects Endothelial Cells From Apoptosis , 2004, Circulation research.
[24] D. Betteridge,et al. Clinicians' Guide to Lipids and Coronary Heart Disease , 2003 .
[25] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .
[26] G. Lewis,et al. Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[27] R. Robertson,et al. Minireview: Secondary β-Cell Failure in Type 2 Diabetes-A Convergence of Glucotoxicity and Lipotoxicity. , 2002, Endocrinology.
[28] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.
[29] Timothy McCaffrey,et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.
[30] L. Groop,et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.
[31] I. Goldberg. Diabetic Dyslipidemia: Causes and Consequences , 2001 .
[32] A. Gotto,et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, European heart journal.
[33] D. Rudy,et al. Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance , 2000, The Journal of Biological Chemistry.
[34] B. Sobel,et al. A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering , 1999, Journal of cardiovascular risk.
[35] Betteridge. Diabetic dyslipidaemia , 1999, European journal of clinical investigation.
[36] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[37] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[38] L. Wilhelmsen,et al. Diabetes and Long-Term Risk of Mortality From Coronary and Other Causes in Middle-Aged Swedish Men: A general population study , 1998, Diabetes Care.
[39] S. Lillioja,et al. Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action , 1997, Diabetes.
[40] J. Abe,et al. Big Mitogen-activated Protein Kinase 1 (BMK1) Is a Redox-sensitive Kinase* , 1996, The Journal of Biological Chemistry.
[41] G. Lewis,et al. Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state , 1996, Diabetes Care.
[42] P. Maloney,et al. Exchange of Aspartate and Alanine , 1996, The Journal of Biological Chemistry.
[43] D. Stafforini,et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.
[44] A. Boulton,et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[45] R. Krauss. Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk , 1994, Current opinion in lipidology.
[46] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[47] P. Gambert,et al. Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetes. , 1992, Diabete & metabolisme.
[48] H. Ginsberg,et al. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. , 1991, The Journal of biological chemistry.
[49] P. Savage,et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. , 1990, American journal of epidemiology.
[50] J V Castell,et al. Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.
[51] P. Strålfors,et al. Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. , 1989, European journal of biochemistry.
[52] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[53] G. Roglić,et al. Mortality attributable to diabetes: estimates for the year 2010. , 2010, Diabetes research and clinical practice.
[54] S. Schinner. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[55] L. Ruilope,et al. The ADVANCE Trial , 2009, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[56] J. Bigger,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group , 2008 .
[57] K. Channon,et al. Endothelial Nox 2 Overexpression Potentiates Vascular Oxidative Stress and Hemodynamic Response to Angiotensin II Studies in Endothelial-Targeted Nox 2 Transgenic Mice , 2007 .
[58] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.
[59] H. Minuk,et al. Metabolic syndrome. , 2005, Journal of insurance medicine.
[60] B. Hoogwerf,et al. Nutrition principles and recommendations in diabetes. , 2004, Diabetes care.
[61] S. Haffner. Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.
[62] J. McGarry. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.
[63] G. Lewis,et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. , 1995, The Journal of clinical investigation.
[64] P. Knight,et al. Epidemiology and Pathophysiology , 1990 .
[65] J. Canivet,et al. [Secondary hyperlipidemia]. , 1965, La Revue du praticien.
[66] SISTER MARY HILAIRE. The diabetic patient. , 1948, Hospital progress.